Does the media refer more to AVR or EMBC?

In the previous week, Embecta had 29 more articles in the media than Anteris Technologies Global. MarketBeat recorded 34 mentions for Embecta and 5 mentions for Anteris Technologies Global. Anteris Technologies Global's average media sentiment score of 1.49 beat Embecta's score of 0.08 indicating that Anteris Technologies Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 2 Very Positive mention(s) 0 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, EMBC or BBNX?

Embecta has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.04B 0.19 $95.40M $1.90 1.73 Beta Bionics $110.24M 6.41 -$73.20M -$1.51 N/A

Is EMBC or BBNX more profitable?

Embecta has a net margin of 10.73% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% Beta Bionics -60.27% -23.00% -20.55%

Does the media prefer EMBC or BBNX?

In the previous week, Embecta had 30 more articles in the media than Beta Bionics. MarketBeat recorded 34 mentions for Embecta and 4 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.80 beat Embecta's score of 0.08 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 2 Very Positive mention(s) 0 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, SIBN or EMBC?

Embecta has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $206.22M 3.57 -$18.90M -$0.39 N/A Embecta $1.04B 0.19 $95.40M $1.90 1.73

Is SIBN or EMBC more profitable?

Embecta has a net margin of 10.73% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Embecta 10.73% -23.96% 14.12%

Does the media favor SIBN or EMBC?

In the previous week, Embecta had 30 more articles in the media than SiBone. MarketBeat recorded 34 mentions for Embecta and 4 mentions for SiBone. SiBone's average media sentiment score of 1.31 beat Embecta's score of 0.08 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 2 Very Positive mention(s) 0 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SSII or EMBC?

In the previous week, Embecta had 25 more articles in the media than SS Innovations International. MarketBeat recorded 34 mentions for Embecta and 9 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 0.51 beat Embecta's score of 0.08 indicating that SS Innovations International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 2 Very Positive mention(s) 0 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SGP or EMBC?

In the previous week, Embecta had 25 more articles in the media than Spyglass Pharma. MarketBeat recorded 34 mentions for Embecta and 9 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 0.30 beat Embecta's score of 0.08 indicating that Spyglass Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 2 Very Positive mention(s) 0 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Embecta (EMBC) Competitors

$3.29 +0.04 (+1.23%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.30 +0.00 (+0.15%)

As of 07/24/2026 07:34 PM Eastern

Compare

EMBC vs. AVR, BBNX, SIBN, SSII, and SGP

Should you buy Embecta stock or one of its competitors? MarketBeat compares Embecta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Embecta include Anteris Technologies Global (AVR), Beta Bionics (BBNX), SiBone (SIBN), SS Innovations International (SSII), and Spyglass Pharma (SGP). These companies are all part of the "medical equipment" industry.

How does Embecta compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

93.8% of Embecta shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Anteris Technologies Global presently has a consensus price target of $16.00, suggesting a potential upside of 96.80%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 234.35%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Anteris Technologies Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

In the previous week, Embecta had 29 more articles in the media than Anteris Technologies Global. MarketBeat recorded 34 mentions for Embecta and 5 mentions for Anteris Technologies Global. Anteris Technologies Global's average media sentiment score of 1.49 beat Embecta's score of 0.08 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	2 Very Positive mention(s)	0 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	414.33	-$94.14M	-$2.23	N/A
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73

Anteris Technologies Global has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Embecta has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Embecta has a net margin of 10.73% compared to Anteris Technologies Global's net margin of -5,148.78%. Embecta's return on equity of -23.96% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%
Embecta	10.73%	-23.96%	14.12%

Summary

Embecta beats Anteris Technologies Global on 10 of the 16 factors compared between the two stocks.

How does Embecta compare to Beta Bionics?

Embecta (NASDAQ:EMBC) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Embecta has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73
Beta Bionics	$110.24M	6.41	-$73.20M	-$1.51	N/A

In the previous week, Embecta had 30 more articles in the media than Beta Bionics. MarketBeat recorded 34 mentions for Embecta and 4 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.80 beat Embecta's score of 0.08 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	2 Very Positive mention(s)	0 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Embecta has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market.

Embecta has a net margin of 10.73% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Beta Bionics	-60.27%	-23.00%	-20.55%

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 234.35%. Beta Bionics has a consensus price target of $20.30, suggesting a potential upside of 28.08%. Given Embecta's higher possible upside, equities research analysts clearly believe Embecta is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Embecta beats Beta Bionics on 9 of the 17 factors compared between the two stocks.

How does Embecta compare to SiBone?

SiBone (NASDAQ:SIBN) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Embecta had 30 more articles in the media than SiBone. MarketBeat recorded 34 mentions for Embecta and 4 mentions for SiBone. SiBone's average media sentiment score of 1.31 beat Embecta's score of 0.08 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	2 Very Positive mention(s)	0 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

98.1% of SiBone shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SiBone presently has a consensus price target of $23.50, suggesting a potential upside of 41.40%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 234.35%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Embecta has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.57	-$18.90M	-$0.39	N/A
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73

Embecta has a net margin of 10.73% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Embecta	10.73%	-23.96%	14.12%

Summary

Embecta beats SiBone on 9 of the 16 factors compared between the two stocks.

How does Embecta compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Embecta (NASDAQ:EMBC) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Embecta has a net margin of 10.73% compared to SS Innovations International's net margin of -20.69%. SS Innovations International's return on equity of -23.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Embecta	10.73%	-23.96%	14.12%

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SS Innovations International currently has a consensus target price of $7.00, suggesting a potential upside of 101.73%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 234.35%. Given Embecta's stronger consensus rating and higher probable upside, analysts clearly believe Embecta is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Embecta has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$48.47M	14.33	-$12.13M	-$0.05	N/A
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73

In the previous week, Embecta had 25 more articles in the media than SS Innovations International. MarketBeat recorded 34 mentions for Embecta and 9 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 0.51 beat Embecta's score of 0.08 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	2 Very Positive mention(s)	0 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SS Innovations International has a beta of -1.96, meaning that its stock price is 296% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Summary

Embecta beats SS Innovations International on 12 of the 15 factors compared between the two stocks.

How does Embecta compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Embecta (NASDAQ:EMBC) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Embecta has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Embecta has a net margin of 10.73% compared to Spyglass Pharma's net margin of 0.00%. Spyglass Pharma's return on equity of 0.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Embecta	10.73%	-23.96%	14.12%

Spyglass Pharma presently has a consensus price target of $45.00, suggesting a potential upside of 119.62%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 234.35%. Given Embecta's higher possible upside, analysts plainly believe Embecta is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

In the previous week, Embecta had 25 more articles in the media than Spyglass Pharma. MarketBeat recorded 34 mentions for Embecta and 9 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 0.30 beat Embecta's score of 0.08 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	2 Very Positive mention(s)	0 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Embecta beats Spyglass Pharma on 9 of the 13 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EMBC vs. The Competition

Export

Metric	Embecta	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$195.19M	$9.51B	$6.87B	$12.26B
Dividend Yield	1.23%	1.64%	2.67%	9.79%
P/E Ratio	1.73	25.73	27.14	23.64
Price / Sales	0.19	25.85	517.06	88.99
Price / Cash	0.81	142.74	50.54	59.64
Price / Book	-0.30	6.11	10.28	6.07
Net Income	$95.40M	$179.69M	$3.60B	$331.99M
7 Day Performance	1.23%	-3.06%	-1.27%	-0.63%
1 Month Performance	5.79%	0.49%	-0.37%	-2.00%
1 Year Performance	-71.95%	9.52%	18.30%	13.62%

Embecta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EMBC Embecta	4.3967 of 5 stars	$3.29 +1.2%	$11.00 +234.3%	-71.1%	$195.19M	$1.04B	1.73	1,850	Trending News
AVR Anteris Technologies Global	3.1381 of 5 stars	$8.04 -2.1%	$16.00 +98.9%	+147.9%	$783.30M	$1.91M	N/A	138	News Coverage
BBNX Beta Bionics	3.2371 of 5 stars	$17.55 -1.5%	$20.30 +15.7%	+9.8%	$781.23M	$100.25M	N/A	294	News Coverage
SIBN SiBone	3.7156 of 5 stars	$17.32 +1.1%	$23.50 +35.7%	-4.3%	$767.70M	$200.93M	N/A	350	News Coverage Analyst Upgrade
SSII SS Innovations International	1.6904 of 5 stars	$3.69 -1.7%	$7.00 +90.0%	-51.8%	$737.48M	$42.49M	N/A	4	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EMBC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Embecta (EMBC) Competitors

EMBC vs. AVR, BBNX, SIBN, SSII, and SGP

How does Embecta compare to Anteris Technologies Global?

Summary

How does Embecta compare to Beta Bionics?

Summary

How does Embecta compare to SiBone?

Summary

How does Embecta compare to SS Innovations International?

Summary

How does Embecta compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Embecta (EMBC) Competitors

EMBC vs. AVR, BBNX, SIBN, SSII, and SGP

How does Embecta compare to Anteris Technologies Global?

Do institutionals & insiders have more ownership in AVR or EMBC?

Do analysts rate AVR or EMBC?

Does the media refer more to AVR or EMBC?

Which has stronger valuation and earnings, AVR or EMBC?

Which has more risk & volatility, AVR or EMBC?

Is AVR or EMBC more profitable?

Summary

How does Embecta compare to Beta Bionics?

Which has preferable valuation & earnings, EMBC or BBNX?

Does the media prefer EMBC or BBNX?

Do insiders & institutionals hold more shares of EMBC or BBNX?

Which has more volatility & risk, EMBC or BBNX?

Is EMBC or BBNX more profitable?

Do analysts rate EMBC or BBNX?

Summary

How does Embecta compare to SiBone?

Does the media favor SIBN or EMBC?

Which has more volatility & risk, SIBN or EMBC?

Do insiders and institutionals have more ownership in SIBN or EMBC?

Do analysts recommend SIBN or EMBC?

Which has better valuation and earnings, SIBN or EMBC?

Is SIBN or EMBC more profitable?

Summary

How does Embecta compare to SS Innovations International?

Is SSII or EMBC more profitable?

Do insiders & institutionals have more ownership in SSII or EMBC?

Do analysts prefer SSII or EMBC?

Which has preferable earnings & valuation, SSII or EMBC?

Does the media refer more to SSII or EMBC?

Which has more risk and volatility, SSII or EMBC?

Summary

How does Embecta compare to Spyglass Pharma?

Which has stronger valuation & earnings, SGP or EMBC?

Do insiders and institutionals have more ownership in SGP or EMBC?

Is SGP or EMBC more profitable?

Do analysts prefer SGP or EMBC?

Does the media prefer SGP or EMBC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools